Allena Pharmaceuticals, Inc. (ALNA) Research

Allena Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and market introduction of orally administered enzyme therapies. Operating within the United States, the firm is dedicated to addressing debilitating metabolic and renal conditions, particularly those that are rare and severe. Its primary therapeutic candidate, ALLN-346, is an innovative enzyme designed to break down urate. This treatment is specifically aimed at individuals experiencing hyperuricemia and gout, especially when these conditions coexist with advanced chronic kidney disease. Established in 2011, Allena Pharmaceuticals maintains its corporate headquarters in Newton, Massachusetts.

Market snapshot

Symbol
ALNA
Price
$0.08
Day change
+3.16%
Market cap
$19.3M
P/E ratio
-0.07x
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Apexigen, Inc. (APGN)
  • Channel Therapeutics Corporation (CHRO)
  • CervoMed Inc. (CRVO)
  • COSCIENS Biopharma Inc. (CSCI)
  • ESSA Pharma Inc. (EPIX)
  • IMV Inc. (IMVIF)
  • Omega Therapeutics, Inc. (OMGA)
  • TNF Pharmaceuticals, Inc. (TNFA)

Recent insider activity

  • Katz Richard D — A-Award (255000 shares) on 2022-02-01
  • BRENNER LOUIS MD — A-Award (655000 shares) on 2022-02-01
  • BRENNER LOUIS MD — M-Exempt (125582 shares) on 2021-11-15
  • BRENNER LOUIS MD — S-Sale (40328 shares) on 2021-11-15
  • BRENNER LOUIS MD — M-Exempt (125582 shares) on 2021-11-15

Open Allena Pharmaceuticals, Inc. (ALNA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.